

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 39/145, 39/00, 39/12, 35/76, C12N 7/04, 7/06		A1	(11) International Publication Number: WO 97/14434 (43) International Publication Date: 24 April 1997 (24.04.97)
(21) International Application Number: PCT/US95/14870 (22) International Filing Date: 20 October 1995 (20.10.95) (71) Applicants (for all designated States except US): DAVIDSON, Clifford, M. [US/US]; 443 Fawns Run, Morganville, NJ 07751 (US). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; 46 Jabotinsky Street, P.O. Box 4279, 91042 Jerusalem (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): ZAKAY-RONES, Zichria [IL/IL]; 52/A Hapalmach Street, 92583 Jerusalem (IL). LEVY, Reuven [IL/IL]; 20 Halamed He Street, 93661 Jerusalem (IL). (74) Agents: RASKIN, Martin, G. et al.; Steinberg, Raskin & Davidson, P.C., 1140 Avenue of the Americas, New York, NY 10036 (US).			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: INFLUENZA VACCINE			
(57) Abstract The invention provides an influenza vaccine which comprises a heat inactivated whole virus influenza free of formalin and B-propionolactone (PBL).			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INFLUENZA VACCINE

The present invention relates to an influenza vaccine.

More particularly the present invention relates to an inactivated whole virus influenza vaccine and to a method for the preparation thereof.

Influenza virus infection still continues to be an annual threat all over the world. The infection may be asymptomatic or may range from a mild upper respiratory infection to a severe disease complicated by pneumonia that may result in mortality. Although severe disease is more frequent in the very young, the chronically ill and the aged, the economic burden of the disease, even when mild, is enormous in the total number of working days lost.

The preferred strategy to control the disease is still annual routine immunization. For over twenty years it has been recommended that killed influenza vaccine be given annually to all persons with high risk conditions. The guiding principle behind the recommendation has been to reduce the mortality of epidemic influenza, morbidity and to prevent complications.

Inactivated virus vaccines are still today the primary tool used for inoculation against influenza.

Vaccines which are at present employed are whole virion inactivated vaccines wherein inactivation has been effected by using

formalin or B-propiolactone (BPL). Also subunit or split vaccines are used for intramuscular (i.m) or subcutaneous (s.c.) immunization.

Live attenuated (i.e. temperature sensitive mutants) are suggested for intranasal (i.n.) application by instillation, aerosol or spray. Most of these vaccines, however, are still only experimental.

The routinely used vaccines purified on sucrose gradient by continuous flow centrifugation, are mostly inactivated by formal, and are whole virions, split or subunit (the latter being aimed especially for children), administered i.m. or s.c. by injection. The efficacy of the vaccines are mostly assessed by seroconversion or by x4 fold rise of humoral antibodies, mainly the hemagglutination inhibition antibodies.

The hemagglutinin of influenza virus is the major surface glycoprotein against which neutralizing antibodies are elicited, however, the isolated glycoproteins obtained by various methods (subunits, genetic engineered or synthetic) is antigenically inferior to whole virus, in producing humoral antibody response and an adjuvant might therefore be required. Moreover, the isolated antigen is not suitable for cases where IgA is the major protective antibody, as is the case in the respiratory tract.

In respiratory tract infections, antibodies of the secretory IgA type have a major role in the defence vs. infection as it neutralizes the virus at its entrance site.

The inactivated vaccines (whole or subunit) are incapable of inducing local antibody production at all or only in negligible level. At the most, a subunit vaccine of the virus can trigger a secondary response and only when it follows a first dose of active virus and not inactive, or subunit. Satisfactory local immunization is therefore not yet available as it is mostly attributed to the presence of live antigen and adequate and safe live vaccines are not yet available.

Beside humoral antibodies, cellular immune response (CMI) is also elicited. In that respect whole virus vaccines are also important. Recently more and more data has been gathered about the importance of CMI in the protection against infection with influenza virus. Cellular immunity is important in that it exhibits cross reactivity among the different strains within the A group, in contrast to the strain specificity of the antibody response. This phenomenon is dependent on the presence of several viral proteins such as the matrix and nucleoprotein. These proteins were conserved during decades as compared to the annual changes in the surface glycoproteins (hemmagglutinin and neuraminidase), which are mainly responsible for the antibody production.

- 4 -

There is great controversy over the safety and efficacy of the current killed vaccine. The use of BPL which was used in the past for inactivation is now prohibited due to its carcinogenicity. Formalin which is still widely used, is responsible for part of the side effects, and recently some doubts as to its safety were raised.

With this state of the art in mind, the present invention provides an influenza vaccine comprising a formalin-and B-propiolactone (BPL) free, heat-inactivated, whole virus influenza.

The invention also provides a process for inactivating whole virus influenza comprising heating harvested allantoic fluid containing influenza virus at a temperature of about 45°-59°C for about 25-180 minutes whereby there is produced a formalin-and BPL-free, heat-inactivated, influenza whole virus, said virus being at least 99% inactivated.

In a preferred embodiment of the present invention said virus is combined with a non-carcinogenic inactivating agent to supplement said heat inactivation to inactivate all residual virus.

Preferably said inactivating agent is thimerosal in combination with ethyl ether. Thimerosal can be combined with the virus while it is subjected to heat inactivation or thereafter.

The inactivation procedure of the present invention, eliminates inactivation which is dependent on the use of biohazard chemicals. Such chemicals as BPL and/or formalin reduce safety of the vaccine and might be also reactogenic. Therefore, the inactive vaccine of the present invention, highly purified by a modified zonal purification procedure is safer, since BPL, formalin or any other carcinogenic chemical is not used. Moreover, the inactivated vaccine of the present invention evokes humoral antibodies following i.m. or i.p. injection to mice, similar to formalin inactivated vaccine, injected by the same route. What is more important - contrary to other inactive antigens, heat inactivated vaccine is still capable of evoking local antibody response against the surface glycoproteins. Also humoral antibodies are elicited in high protective levels, which persist for long periods. The heat inactivated antigen can also induce interferon in low levels. Interferon was not induced by formalin treated antigen.

The present vaccine is safer and more efficient and, being an inactive zonal purified whole virus vaccine, it can substitute for the routinely used vaccine for intramuscular and subcutaneous application, and also be used as a new vaccine for local intranasal application. This is an important step forward in the efforts to improve influenza vaccines. This vaccine would greatly enlarge the groups for targeting killed vaccine.

The purification procedure results in a vaccine containing a low concentration of protein, which minimizes to almost zero, adverse side effects.

The present method for the inactivation of influenza viruses is of great importance, as BPL previously used is banned from further use due to its carcinogenicity. Formalin which is still widely used has lately elicited doubts as to its safety.

The mode of inactivation is therefore of great advantage, as compared to the routinely inactivated vaccines which are in use.

The vaccine can substitute the routinely used formol inactivated vaccine injected i.m. or s.c. with similar level of humoral antibodies being produced.

The vaccine can be applied intranasally. Using this route of application, similar protective level of humoral antibodies are elicited, as well as local antibodies.

While the invention will now be described in connection with certain preferred embodiments in the following examples so that aspects thereof may be more fully understood and appreciated, it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives,

modifications and equivalents as may be included within the scope of the invention as defined by the appended claims. Thus, the following examples which include preferred embodiments will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of formulation procedures as well as of the principles and conceptual aspects of the invention.

Examples

Preparation and purification of whole virion inactive influenza vaccine.

Allantoic fluids from infected embryonated eggs (10-12 days old), 40-60 hr past infection is harvested following overnight refrigeration or 45 min at -20°C and subjected to concentration and purification.

Clarified harvested allantoic fluid was subjected to heat inactivation at a temperature of about $55-56^{\circ}$ for 30 minutes in a water bath. Inactivation was carried out in the presence of merthiolate (Thiomersal) 1:20,000 final concentration or without. Following inactivation the antigen was purified and the purified antigen was suspended in buffer pH 7.2-4. Final antigen containing 6-7% sucrose, thiomersal 0.01% and ether 1%-2%. The residual virus is

- 8 -

inactivated by the thiomersal and ether as tested in embryonated eggs.

The final product: 60-80 ug protein

5-6% sucrose

PO_4 0.1M 0.15 NaCl pH 7.8-7.9

10^{-3} M EDTA

0.01% Thiomersal

0.05% Tween 80

0.01%-0.02% ether

The following influenza strains were heat inactivated

A/Taiwan/86 (NIB-16) (H_1N_1)

A/PR8/34 (H_1N_1)

A/Leningrad 360/86 (H_3N_2)

B/Ann Arbor

A/Taiwan/1/86 (H_1H_1) was chosen since it is a recent strain in the current vaccine.

A/PR8/34 (H_1N_1) strain was chosen since it serves as a parental strain in many recombinants designated for vaccine preparation and the strain is pathogenic to mice, and therefore challenge experiments can be performed in the immunized animals. A/Leningrad 360/86 was chosen as a representative of A/ H_3N_2 strain and B/Ann Arbor was chosen as a representative of a BN strain type of virus.

Table 1
Infectivity Inactivation Following Heat Treatment

Allantoic fluid (following clarification)

<u>Strain/Treatment</u>	<u>none</u>	<u>55-56° 30'</u>	<u>55-56°-30' +1/20000 Thiomersal</u>	<u>45°-3h.</u>	<u>59° 30'</u>
A/Taiwan 1/86 (H ₁ N ₁)	10 ^{8.5} 10 ^{8.5}	10 ^{4.5} 10 ^{3.7}	n.d. n.d.	10 ^{5.0}	n.d. (not done) n.d.
A/PR ₈ /34 (H ₁ N ₁)	10 ^{9.0} 10 ^{8.0} 10 ^{8.5}	10 ^{2.0} 10 ^{3.5} 10 ^{3.5}	10 ^{1.0} 10 ^{2.8} 10 ^{3.0}	n.d.	n.d. 10 ^{1.24}
B/Ann Arbor	10 ^{9.5}	10 ^{4.5}	n.d.	n.d.	n.d.
A/Leningrad (H3N2) 360/86	10 ^{7.5}	10 ^{2.5}	n.d.	n.d.	n.d.

a. Infectivity measured by titration in allantoic sac of embryonated eggs and determined as EID₅₀/0.2 ml.

From Table 1 it can be seen that with all four representative strains heating at 55°-56°C for 30 minutes resulted in over 99% decrease in infectivity.

Addition of Thiomersal during heat inactivation further decreased the infectivity of the tested APR₈ strain.

Heating at 45°C for 3 hours and at 59°C for 30 minutes were also effective for decreasing infectivity by over 99%.

In Table 2 hereinafter it can be seen that the inactivation according to the present invention does not cause deterioration of

- 10 -

hemagglutination activity of the virus thus assuring that the use of the inactivated virus will nevertheless result in the formation of the desired immunity including the formation of antibodies.

It is to be noted that even the decrease in activity resulting from heating at 59°C for 30 minutes is not considered significant in the context of the test done.

Table 2

Effect of Heat on Hemagglutination Titer of Allantoic Fluid

<u>Strain/Treatment</u>	<u>none</u>	<u>55-56° 30'</u>	<u>55-56°-30' +1/20000 Thiomersal</u>	<u>45°-3h.</u>	<u>59° 30'</u>
A/Taiwan 1/86 (H ₁ N ₁)	1000-2000 2000-4000	1000-2000 2000-4000	n.d. n.d.	1000 n.d.	
A/PR ₈ /34 (H ₁ N ₁)	1024 2000 1024	1024 2000 1024	n.d. 2000 1024	n.d. n.d.	 512
B/Ann Arbor	1024	1024			
A/Leningrad (H3N2) 360/86	1000	512-1000			

The purified suspensions of two of the above viral strains (2 batches of each) were further purified and were found inactive and sterile in bacteriological tests and were tested for the immunogenicity.

Table 3Inactivity of concentrated purified material

<u>Strain/Treatment</u>		<u>Thiomersal and Ether</u>
A/Taiwan 1/86 (H ₁ N ₁)	10 ^{4.2}	negative
	10 ^{3.5}	negative
A/PR8/34 (H ₁ N ₁)	10 ^{4.0}	negative
	10 ^{3.7}	negative

As can be seen from Table 3, residual infectivity in allantoic fluid was completely diminished in the purified concentrated virus suspension by further treatment with Thiomersal 1:10000 final concentration and ether 1-2%.

II. Immunological Studies

Mice were immunized interaperitoneally (i.p.) (0.5ml) or i.n. 005-0.1ml. At several time intervals titers of hemagglutination inhibition HI antibodies were tested.

In accordance with accepted protocol vaccine according to the invention was evaluated 21 days following mice immunization either i.p. or i.n.

The results are tabulated in Table 4 from which it can be seen that substantially 100% of the mice tested responded with high protective levels of humoral antibodies.

As shown in Table 5 antibodies were still present two months following immunization with protective levels of humoral antibodies still being in the range and magnitude recognized as affording protection.

Table 4

Humoral hemagglutination inhibition antibodies (HI) 21 days following immunization of mice with heat inactivated vaccines

Strain	route of vaccination	vaccine dilution	no of mice responding	HI antibodies*
A/Taiwan 1/86 (H ₁ N ₁)	i.p.	1:10	9/9	380
	i.p.	1:10	9/9	100
	i.n.	1:5*	7/7	60
A/PR8/34 (H ₁ N ₁)	i.p.	1:25	7/8	365
	i.n.	1:5	14/14	240
	i.m.	1:5	10/10	160

* Average reciprocal titer of hemagglutination inhibitions antibodies.

Each mice was tested individually.

Table 5

Persistence of humoral antibodies two months following immunization with heated A/PR₈/34

<u>Route of Vaccination</u>	<u>No. of mice responding</u>	<u>HI antibodies^a</u>
i.p.	14/16	28.4
i.n.	9/14	30.0
i.n.x2 ^b	4/4	91.0
i.n. ^c	9/9	55.5

^a Average of reciprocal of HI antibody titer.

^b Mice were immunized twice with 12 days interval between immunization.

^c Mice were inoculated with live virus, for control purposes.

Comparative Example A

A/PR₈/34 strain vaccine was prepared according to the present method of inactivation and a similar vaccine was prepared using state of the art inactivation with formalin.

- 13 -

The two vaccines were then administered intranasally to two different groups of mice and the mice were tested individually 10 and 20 days after immunization.

As can be seen in the results tabulated in Table 6, humoral antibody response was significantly higher with the vaccine inactivated according to the present invention and only with the present vaccine was local antibody response elicited also in the lungs.

Table 6

Humoral and local antibodies following
intranasal immunization with A/PR8/34

Vaccine day	heated		formol	
	humoral	local in lungs	humoral	local in lung
10	160	16	40	negative
20	160	32	40	negative

Comparative Example B

Mice were immunized with vaccine inactivated according to the present invention which vaccine was administered intranasally. A second group of mice which were not immunized were kept as controls. Mice were challenged 21 days following immunization and the results of said challenge experiments on the immunized and controlled mice are set forth in Table 7. As will be noted, in the first group experiment of the mice vaccinated none were found to be sick or dead while 75% of the control mice were found to be sick and 25% were found to be dead.

In the second group of experiments one out of the fourteen mice immunized was found to be dead while 21 out of 29 of the control mice were found to be dead.

Table 7

Challenge experiments following intranasal
immunization with heated A/PR8/34

	Vaccine	No. of mice	sick	dead
7a	A/PR8	8	0	0
	Control	8	6/8 (75%)	2/8 (25%)
7b	A/PR8	14	0	1/14 (7%)
	Control	29	0	21/29 (72.4%)

Table 8

Immunization of mice with 3 months old vaccine (A/PR8)
(Shelf-life test)

Route of Immunization	Antigen Dilution	Number of mice Responding	HI titer*
i.p.	1:10	9/10	180
i.p.	1:25	8/9	240
i.n.	1:5	10/10	68

* Average of reciprocal of HI titer.

It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is therefore desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

- 16 -

WHAT IS CLAIMED IS:

1. An influenza vaccine comprising a heat inactivated whole virus influenza free of formalin and B-propiolactone (BPL).
2. A vaccine according to claim 1 further comprising thimerosal.
3. A vaccine according to claim 1 further comprising ethyl ether.
4. A vaccine according to claim 1 together with instructions for intranasal administration thereof.
5. A process for inactivating whole virus influenza comprising heating harvested allantoic fluid containing influenza virus at a temperature of about 45°-59°C for about 25-180 minutes whereby there is produced a formalin and BPL free heat inactivated influenza whole virus, said virus being at least 99% inactivated.
6. A process according to claim 5 comprising combining said virus with a non-carcinogenic inactivating agent to supplement said heat inactivation to inactivate all residual virus.
7. A process according to claim 6 wherein said inactivating agent is thimerosal.

8. A process according to claim 6 wherein said inactivating agent is thimerosal in combination with ethyl ether.

9. A method for influenza vaccination comprising administering intranasally an influenza vaccine comprising heat inactivated whole virus influenza free of formalin and B-propiolactone (BPL).

10. A method for influenza vaccination according to claim 9 wherein said vaccine is administered intranasally by spray.

11. A method for influenza vaccination according to claim 9 wherein said vaccine is administered intranasally by drops.

12. A method for influenza vaccination comprising administering intramuscularly an influenza vaccine comprising heat inactivated whole virus influenza free of formalin and B-propiolactone (BPL).

13. A method for influenza vaccination comprising administering subcutaneously an influenza vaccine comprising heat inactivated whole virus influenza free of formalin and B-propiolactone (BPL).

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/14870

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 39/145, 39/00, 39/12, 35/76; C12N 7/04, 7/06

US CL :424/209.1, 206.1; 435/236, 238

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/209.1, 206.1; 435/236, 238

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Medline, Derwent WPI, INPADOC search terms: influenza, vaccine, thimersol, merthiolate, thiomersol

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 3,060,094 (DUTCHER ET AL.) 23 October 1962, see example 2.	1, 4, 12
Y		2, 3, 6-11, 13
Y	US, A, 3,655,871 (WERNER ET AL.) 11 April 1972, see column 1 lines 55-70 and column 3 lines 47-50.	2, 3, 6, 7, 8
Y	PLOTKIN ET AL., "VACCINES", published 1988 by Saunders Company (Philadelphia, Pa.), pages 420-434, see page 424.	9-13

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

31 JANUARY 1996

Date of mailing of the international search report

27 FEB 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

LAWRENCE J. CARROLL, II

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196